Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells

Oral and Maxillofacial Surgery

Volumn 14, Issue 1, 2010, Pages 53-57

  Scheer, Martin ^a   Drebber, Uta ^a   Breuhahn, Kai ^b   Möckel, Christoph ^c   Reuther, Tobias ^d   Kern, Michael ^b   Zöller, Joachim E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c St Franziskus Hospital Koln   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

COX 2 inhibitors; Cyclooxygenase 2; Hypopharyngeal cancer; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN 5; CYTOKERATIN 6; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER STAGING; CELL CULTURE; COMPUTER ASSISTED TOMOGRAPHY; FRONTAL BONE; HUMAN; HYPOPHARYNX TUMOR; MALE; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PLASTIC SURGERY; RADIOGRAPHY; SKULL TUMOR; SQUAMOUS CELL CARCINOMA; TEMPORAL BONE;

CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; CYCLOOXYGENASE 2; FRONTAL BONE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KERATIN-5; KERATIN-6; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; SKULL NEOPLASMS; SURGICAL FLAPS; TEMPORAL BONE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 76649134427     PISSN: 18651550     EISSN: 18651569     Source Type: Journal    
DOI: 10.1007/s10006-009-0181-5     Document Type: Article

References (25)

1. Vane J (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat New Biol 231: 232-235.
2. Chandrasekharan NV, Dai H, Roos KL et al (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931.
3. Herschmann HR (1996) Prostaglandin synthase 2. Biochem Biophys Acta 1299: 125-140.
4. Tsuji M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83: 493-501.
5. Kern MA, Schubert D, Sahi D et al (2002) Proapoptotic and antiproliferate potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36: 885-894.
6. Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
7. Visscher DW, Pankratz VS, Santisteban M et al (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100: 421-427.
8. Gupta S, Srivastava M, Ahmad N et al (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78.
9. Hida T, Yatabe Y, Achiwa H et al (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764.
10. Reddy BS, Hirose Y, Lubet R et al (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297.
11. Chan G, Boyle JO, Yang EK et al (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994.
12. Goto R, Hoshikawa H, Fujii T et al (2008) Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma. Oncol Rep 19: 645-650.
13. Peng JP, Su CY, Chang HC et al (2002) Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 33: 100-104.
14. Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340.
15. Gallo O, Fabbroni V, Sardi I et al (2002) Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299: 517-524.
16. Gallo O, Masini E, Bianchi B et al (2002) Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33: 708-714.
17. Woolgar JA, Hall GL (2009) Determinants of outcome following surgery for oral squamous cell carcinoma. Future Oncol 5: 51-61.
18. Greenhough A, Smartt HJ, Moore AE et al (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
19. Buchanan FG, Wang D, Bargiacchi F et al (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457.
20. Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356.
21. Furuta Y, Hall ER, Sanduja S et al (1988) Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 48: 3002-3007.
22. Asea A, Mallick R, Lechpammer S et al (2001) Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation. Int J Hypertherm 17: 401-414.
23. Davis TW, O'Neal JM, Pagel MD et al (2004) Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64: 279-285.
24. Kazanov D, Dvory-Sobol H, Pick M et al (2004) Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 10: 267-271.
25. Shar AO, Gaudard MA, Heath EI et al (2009) Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. Contemp Clin Trials 30: 2-7.